Analysts have been eager to weigh in on the Healthcare sector with new ratings on Amarin (AMRN – Research Report) and Travere Therapeutics (TVTX – Research Report).
Amarin (AMRN)
In a report issued on August 22, Roanna Ruiz from SVB Securities reiterated a Hold rating on Amarin. The company’s shares closed last Wednesday at $1.36, close to its 52-week low of $1.11.
According to TipRanks.com, Ruiz is ranked 0 out of 5 stars with an average return of
Amarin has an analyst consensus of Hold, with a price target consensus of $3.17.
See Insiders’ Hot Stocks on TipRanks >>
Travere Therapeutics (TVTX)
SVB Securities analyst Joseph Schwartz reiterated a Buy rating on Travere Therapeutics on August 22. The company’s shares closed last Wednesday at $28.05.
According to TipRanks.com, Schwartz has 0 stars on 0-5 stars ranking scale with an average return of
Travere Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $40.00, which is a 46.5% upside from current levels. In a report issued on August 8, H.C. Wainwright also maintained a Buy rating on the stock with a $42.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on AMRN:
- Analysts Offer Insights on Technology Companies: Blackbaud (BLKB), WEX (WEX) and ForgeRock Inc (FORG)
- Wall Street Analysts Are Bullish on Top Consumer Goods Picks
- Hub Group (HUBG) Gets a Buy from Robert W. Baird
- Plymouth Industrial Reit (PLYM) Gets a Buy from Robert W. Baird
- Analysts Are Bearish on These Materials Stocks: New Hope Corporation Limited (NHPEF), Lynas Rare Earths Limited (LYSCF)
